Nanobiotix (NASDAQ:NBTX) Shares Gap Up – Time to Buy?

Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) shares gapped up before the market opened on Thursday . The stock had previously closed at $20.06, but opened at $21.05. Nanobiotix shares last traded at $21.3790, with a volume of 789 shares traded.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on the company. Wall Street Zen raised Nanobiotix to a “hold” rating in a research report on Saturday, October 25th. Leerink Partners reissued an “outperform” rating on shares of Nanobiotix in a report on Tuesday, November 25th. Weiss Ratings restated a “sell (d-)” rating on shares of Nanobiotix in a research report on Wednesday, October 8th. Finally, HC Wainwright reissued a “buy” rating on shares of Nanobiotix in a report on Tuesday, November 4th. Three investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $11.00.

Nanobiotix Stock Performance

The company has a 50 day simple moving average of $21.53 and a 200 day simple moving average of $16.04.

Institutional Investors Weigh In On Nanobiotix

An institutional investor recently bought a new position in Nanobiotix stock. Optiver Holding B.V. bought a new stake in Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 5,356 shares of the company’s stock, valued at approximately $101,000. 38.81% of the stock is owned by hedge funds and other institutional investors.

Nanobiotix Company Profile

Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company’s lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.

Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.